Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

It's been a pretty great week for Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) shareholders, with its shares surging 14% to US$15.10 in the week since its latest third-quarter results. It was a moderately negative result overall - revenue fell 4.4% short of analyst estimates at US$46m, although at least statutory losses were marginally smaller than expected, at US$0.70 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the current consensus from Syndax Pharmaceuticals' twelve analysts is for revenues of US$376.6m in 2026. This would reflect a huge 238% increase on its revenue over the past 12 months. Losses are predicted to fall substantially, shrinking 65% to US$1.25. Before this earnings announcement, the analysts had been modelling revenues of US$377.6m and losses of US$1.41 per share in 2026. Although the revenue estimates have not really changed Syndax Pharmaceuticals'future looks a little different to the past, with a cut to the loss per share forecasts in particular.

See our latest analysis for Syndax Pharmaceuticals

The average price target held steady at US$38.85, seeming to indicate that business is performing in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Syndax Pharmaceuticals at US$56.00 per share, while the most bearish prices it at US$22.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Syndax Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 165% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 5.0% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 21% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Syndax Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Syndax Pharmaceuticals analysts - going out to 2027, and you can see them free on our platform here.

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.